StockData
Theriva Biologics, Inc. logo

Theriva Biologics, Inc. (TOVX) stock

TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.14+0.00 (+2.86%)

Close on Nov 18, 2026Market cap $6.61MP/E –Yield –

Theriva Biologics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Theriva Biologics's operating income for the twelve months ending Jun 30, 2026 was -$11.93M. For fiscal 2025 it was -$24.05M. The highest annual figure on record is -$10.16M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$24.05M–
FY2024Dec 31, 2024-$26.35M–
FY2023Dec 31, 2023-$21.43M–
FY2022Dec 31, 2022-$21.58M–
FY2021Dec 31, 2021-$14.27M–
FY2020Dec 31, 2020-$10.16M–
FY2019Dec 31, 2019-$15.66M–
FY2018Dec 31, 2018-$17.57M–
FY2017Dec 31, 2017-$26.25M–
FY2016Dec 31, 2016-$39.25M–
FY2015Dec 31, 2015-$40.98M–
FY2014Dec 31, 2014-$20.50M–
FY2013Dec 31, 2013-$12.34M–
FY2012Dec 31, 2012-$17.30M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.30M–
Q1 FY2026Mar 31, 2026-$2.13M–
Q4 FY2025Dec 31, 2025-$2.06M–
Q3 FY2025Sep 30, 2025-$4.44M–
Q2 FY2025Jun 30, 2025-$13.13M–
Q1 FY2025Mar 31, 2025-$4.42M–
Q4 FY2024Dec 31, 2024-$4.58M–
Q3 FY2024Sep 30, 2024-$7.89M–
Q2 FY2024Jun 30, 2024-$8.49M–
Q1 FY2024Mar 31, 2024-$5.39M–
Q4 FY2023Dec 31, 2023-$6.22M–
Q3 FY2023Sep 30, 2023-$4.22M–
Q2 FY2023Jun 30, 2023-$5.82M–
Q1 FY2023Mar 31, 2023-$5.18M–
Q4 FY2022Dec 31, 2022-$7.32M–
Q3 FY2022Sep 30, 2022-$4.99M–
Q2 FY2022Jun 30, 2022-$5.03M–
Q1 FY2022Mar 31, 2022-$4.25M–
Q4 FY2021Dec 31, 2021-$5.27M–
Q3 FY2021Sep 30, 2021-$3.28M–
Q2 FY2021Jun 30, 2021-$3.20M–
Q1 FY2021Mar 31, 2021-$2.54M–
Q4 FY2020Dec 31, 2020-$2.13M–
Q3 FY2020Sep 30, 2020-$2.11M–
Q2 FY2020Jun 30, 2020-$2.89M–
Q1 FY2020Mar 31, 2020-$3.03M–
Q4 FY2019Dec 31, 2019-$3.21M–
Q3 FY2019Sep 30, 2019-$5.24M–
Q2 FY2019Jun 30, 2019-$3.64M–
Q1 FY2019Mar 31, 2019-$3.57M–
Q4 FY2018Dec 31, 2018-$3.26M–
Q3 FY2018Sep 30, 2018-$4.32M–
Q2 FY2018Jun 30, 2018-$5.00M–
Q1 FY2018Mar 31, 2018-$4.99M–
Q4 FY2017Dec 31, 2017-$5.78M–
Q3 FY2017Sep 30, 2017-$5.84M–
Q2 FY2017Jun 30, 2017-$6.48M–
Q1 FY2017Mar 31, 2017-$8.15M–
Q4 FY2016Dec 31, 2016-$10.20M–
Q3 FY2016Sep 30, 2016-$9.16M–

More Theriva Biologics figures

See a number that looks wrong?